Clin Hypertens.  2019 ;25(1):25. 10.1186/s40885-019-0131-y.

Compelling therapy of LVH: straight (and not-so-straight) inferences from evidence

• Mehta RT
• Pareek A
• Dharmadhikari S

• KMID: 2468631
• DOI: http://doi.org/10.1186/s40885-019-0131-y

Abstract

We have read with interest the Korean Society of Hypertension guidelines for the management of hypertension and congratulate the Society for an extensive review of literature while drafting the guidelines. The guidelines indicate preferring ACE-I and CCB over diuretics in patients with left ventricle hypertrophy. However, in landmark head-to-head comparison trials, the thiazide-like diuretic chlorthalidone has been shown to be superior to ACE-I and CCB in decreasing left ventricle mass and preventing heart failure in hypertensive patients. Also, we put forth the paradoxical finding that mere regression of LVH may not always translate into reduction in risk of HF; and that the pleiotropic effects of chlorthalidone may be the explanation behind its beneficial action in HF.

Keyword

Guidelines; Chlorthalidone; Amlodipine; Hypertension; Left ventricle hypertrophy; Heart failure; Thiazide diuretics; Calcium channel blockers; ACE-inhibitors

MeSH Terms

Amlodipine
Calcium Channel Blockers
Chlorthalidone
Diuretics
Heart Failure
Heart Ventricles
Humans
Hypertension
Hypertrophy
Sodium Chloride Symporter Inhibitors
Amlodipine
Calcium Channel Blockers
Chlorthalidone
Diuretics
Sodium Chloride Symporter Inhibitors